CIK 0001280776 · Non-accelerated filer<br>Smaller reporting company
IMMUNIC, INC.
Sign in to watch- Ticker
- IMUX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 562358443
- Phone
- (332) 255-9818
- Business address
- 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK, United States, 10036
- Former names
- VITAL THERAPIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-16 | Whaley Glenn Chief Financial Officer | Grant or award · Stock Appreciation Right | +280,000 | 280,000 | ||
| 2025-07-16 | Whaley Glenn Chief Financial Officer | Grant or award · Stock Appreciation Right | +560,000 | 560,000 | ||
| 2025-07-16 | Whaley Glenn Chief Financial Officer | Grant or award · Stock Appreciation Right | +560,000 | 560,000 | ||
| 2025-07-16 | Whaley Glenn Chief Financial Officer | Grant or award · Stock Appreciation Right | +280,000 | 280,000 | ||
| 2025-07-16 | Whaley Glenn Chief Financial Officer | Grant or award · Stock Appreciation Right | +280,000 | 280,000 | ||
| 2025-07-16 | Nash Duane Executive Chairman | Grant or award · Stock Appreciation Right | +315,000 | 315,000 | ||
| 2025-07-16 | Nash Duane Executive Chairman | Grant or award · Stock Appreciation Right | +630,000 | 630,000 | ||
| 2025-07-16 | Nash Duane Executive Chairman | Grant or award · Stock Appreciation Right | +630,000 | 630,000 | ||
| 2025-07-16 | Nash Duane Executive Chairman | Grant or award · Stock Appreciation Right | +315,000 | 315,000 | ||
| 2025-07-16 | Nash Duane Executive Chairman | Grant or award · Stock Appreciation Right | +315,000 | 315,000 | ||
| 2025-07-16 | Vitt Daniel CEO and Director | Grant or award · Stock Appreciation Right | +860,000 | 860,000 | ||
| 2025-07-16 | Vitt Daniel CEO and Director | Grant or award · Stock Appreciation Right | +1,720,000 | 1,720,000 | ||
| 2025-07-16 | Vitt Daniel CEO and Director | Grant or award · Stock Appreciation Right | +1,720,000 | 1,720,000 | ||
| 2025-07-16 | Vitt Daniel CEO and Director | Grant or award · Stock Appreciation Right | +860,000 | 860,000 | ||
| 2025-07-16 | Vitt Daniel CEO and Director | Grant or award · Stock Appreciation Right | +860,000 | 860,000 | ||
| 2025-07-16 | Muehler Andreas Chief Medical Officer | Grant or award · Stock Appreciation Right | +330,000 | 330,000 | ||
| 2025-07-16 | Muehler Andreas Chief Medical Officer | Grant or award · Stock Appreciation Right | +660,000 | 660,000 | ||
| 2025-07-16 | Muehler Andreas Chief Medical Officer | Grant or award · Stock Appreciation Right | +660,000 | 660,000 | ||
| 2025-07-16 | Muehler Andreas Chief Medical Officer | Grant or award · Stock Appreciation Right | +330,000 | 330,000 | ||
| 2025-07-16 | Muehler Andreas Chief Medical Officer | Grant or award · Stock Appreciation Right | +330,000 | 330,000 |
Page 2 of 9 · 170 trades